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routinely warranted in this patient population. Patients who
require systemic corticosteroids posteHSC may be consid-
ered for PJ prophylaxis.151
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There is little consensus regarding the optimal conditioning
regimen for AHCT for NHL. Thiotepa is an alkylating agent
with anti-lymphoma properties, but it has limited data as a
conditioning agent for AHCT in adult NHL. We report here
long-term results of our institutional experience in NHL
receiving AHCT following HDT with etoposide, cyclophos-
phamide and thiotepa (VP-16/CY/TT). Patients received eto-
poside 1800mg/m2 IV x 1 dose, cyclophosphamide (50mg/
kg/dose IV x 3-4 doses), and thiotepa (250mg/m2/dose e
300mg/m2/dose x 3 doses). Forty-three patients were con-
sented and enrolled from November 1997 to June 2009.Table 1
Baseline Demographics
Characteristics N¼43
Median age, years (range) 55 (27-69)
Male gender, n (%) 22 (51%)
Diagnosis (%)
Diffuse Large B-cell Lymphoma (DLBCL) 23 (54%)
Follicular Lymphoma 7 (16%)
Transformed follicular lymphoma 2 (5%)
Mantle Cell Lymphoma 4 (9%)
T-cell NHL 7 (16%)
Bone Marrow Involvement 10 (23%)
CNS Involvement 2 (5%)
Stage
Early Stage (1&2) 14 (32%)
Advanced Stage (3&4) 27 (63%)
Missing 2 (5%)
IPI
Low (0-1) 17 (40%)
Intermediate (2-3) 23 (54%)
High (4-5) 2 (5%)
Unknown 1 (2%)
Prior therapies, median (range) 2 (1-4)
Remission status before transplant
Complete Remission 1 8 (19%)
Complete Remission 2 17 (40%)
Complete Remission 3 2 (5%)
Partial Remission 16 (37%)
Autologous stem cell source (%)
Peripheral Blood 35 (81%)
Bone Marrow 4 (9%)
Both 4 (9%)
Karnofsky Performance Status,
median (range)
90 (80-100)
Median CD34 cell dose infused (106 cells/kg
recipient), (range)
5.3 (1.8-10.5)Disease characteristics are described in Table 1. Peripheral
blood stem cell mobilization utilized cyclophosphamide
and ﬁlgrastim. All patients received antibacterial, antiviral
(acyclovir), and antifungal (ﬂuconazole) prophylaxis along
with ﬁlgrastim support after stem cell infusion. Median
follow up for surviving patients was 4.7 years (range 0.26
years to 15.85 years). Median time to neutrophil and platelet
engraftment was 13 and 21 days, respectively. Signiﬁcant
regimen-related toxicities included mucositis (51%), neu-
tropenic fever (72%), diarrhea (26%), and pneumonia (9%).
No CNS failures were reported. Secondary malignancies
occurred in 3 patients (7%) e two of which were soft tissue
sarcomas and one MDS/AML. Progression free survival (PFS)
and overall survival (OS) at 5 years was 53% (39% - 71%) and
73% (60% - 89%), respectively. Relapse rates at day +100 and 5
years were 9.4% (95% CI: 2.9% e 20.4%) and 40.1% (95% CI:
24.7% - 55.1%), respectively. Cumulative incidence of non-
relapse mortality at day +100 and 5 years was 4.7% (95% CI:
0.8% - 14.0%) and 7% (95% CI: 1.8% - 17.4%), respectively. VP-
16/Cy/TT is a well-tolerated conditioning regimen for pa-
tients with NHL, with promising long term progression-free
and overall survival rates.152
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We performed a retrospective analysis on patients who un-
derwent PBSC collection and subsequent ASCT at our insti-
tution to assess whether efﬁciency of PBSC mobilization is
predictive of engraftment failure.
Methods: We identiﬁed 369 patients who underwent PBSC
collection between 01/01/2006-8/31/2012 for a ﬁrst ASCT.
We collected data on age, sex, use of lenalidomide or
thalidomide (“Imid”) prior to mobilization, mobilization
regimen, # of collections for ﬁnal cell dose, # of CD34+ cells
infused, and the presence of a positive blood culture within
30 days of ASCT. Quintiles were created for the # of CD34+
cells collected. The primary outcomewas engraftment failure
deﬁned as not achieving an absolute neutrophil count (ANC)
>1000/mL or a platelet count >50,000/mL (no platelet
transfusion in </¼ 7 days) by day 30 post-ASCT. Secondary
outcomes were time to ANC and platelet engraftment. We
performed a multivariate logistic regression analysis to
assess the association of collected CD34+ cells and engraft-
ment failure while adjusting for the other variables. For time
to event analyses we used Cox proportional hazard models.
Results: Median patient age was 58 and 56% were male.
Patient-reported race was: Black (38%), White (17%), and
“Other” (45%). Indications for ASCT were Multiple Myeloma
(45%), Non-Hodgkin Lymphoma (41%), Acute Leukemia (9%),
Hodgkin Lymphoma (3%), Amyloidosis (1%), and Germ Cell
Tumors (1%). The median # of CD34+ cells collected was
7.7x10
ˇ
6/kg (range 2.26-120 x10
ˇ
6/kg) and median # of
CD34+ cells infused was 5.3x10
ˇ
6/kg (2.3-45x10
ˇ
6/kg).
Median # of collections for transplant dosewas 2 (range 1-8).
CD34 cells collected were divided into quintiles (cut points:
6.04, 7.57, 9.86 and 17.7x10
ˇ
6/kg). We found that a higher #
of collected CD34+ cells during mobilization was associated
with less engraftment failure (p¼.0067): every increase in
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engraftment failure (OR 0.60, 95% CI 0.41-0.87). Even when
adjusted for cell dose infused, a higher # of collected CD34+
cells was associated with decreased time to platelet
engraftment (HR1.15, CI 1.00-1.32, p¼.052), but not ANC
engraftment (HR 1.07, p¼.35). Positive blood cultures within
30 days of ASCT were associated with engraftment failure
(p¼.0035), while race, sex, # of collections for the trans-
planted dose and mobilization regimen did not appear to
affect engraftment. We also observed that prior Imid use
demonstrated a trend toward less engraftment failure (OR
0.41, 95%CI 0.17-1.01; p¼.052).
Although a moderate correlation was observed between
the variables CD34 cells collected and CD34 cells infused, a
sensitivity analysis by omitting either variable did not iden-
tify a signiﬁcantly different estimates.153
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Background: The collection of a minimum number of he-
matopoietic stem cells (HSC), generally deﬁned as 2 x 106
CD34+ cells/kg, is a prerequisite for proceeding to HSCT.
Primary mobilization failure occurs in 5 e 40% of patients.1-5
When used to unselected patients undergoing a ﬁrst mobi-
lization attempt, plerixafor plus GCSF allows more CD34+
cells to be mobilization with fewer aphereses than GCSF
alone.6, 7 There are no publications describing the patterns of
plerixafor use at Canadian transplant centres, nor is there
data to guide determinations of cost-effectiveness of mobi-
lization using plerixafor from the Canadian perspective.
Methods: The objectives of this study were to: 1) Summa-
rize the published studies of plerixafor-based mobilization
during compassionate access programs, and 2) Describe the
Canadian experience with plerixafor during its availability
though Health Canada’s Special Access Program (SAP). A
literature search was performed and studies were grouped
into three strategies: upfront, preemptive and salvage. In
Canada, plerixafor was available through the SAP, and fun-
ded by Genzyme/Sanoﬁ from September 2008 to December
2010.
Results: Thirteen articles were identiﬁed. In all but one
study, plerixafor was used as part of a preemptive and/or
salvage strategy. The proportion lf patients in whom a min-
imum of 2 x 106 CD34+ cells/kg was collected ranged from 37
e 100%. At the time of publication, 17 e 87% of patients had
proceeded to transplantation.
Thirteen Canadian centres provided data on a total of 132
patients, the majority of whom had multiple myeloma or
lymphoma, and had undergone a median of 1 prior mobili-
zation attempt (range 0 e 3). Plerixafor was used preemp-
tively in 23 (17%) patients and as salvage in 109 (83%)
patients. In 96 (73%) patients, therewas successful collection.
Of the 23 patients in whom plerixafor was used preemp-
tively, 19 (83%) had successful collections. Of the 109 patients
in whom the drug was used as part of a salvage strategy,
77 (71%) had successful collections. Of the entire cohort,
99 (75%) of patients went on to receive an autologous
transplant.Discussion: Our study summarizes the published experience
with plerixafor-based mobilization during compassionate
drug access programs and describes the Canadian experience
when plerixafor was freely available through Health Cana-
da’s SAP. Canadian practice was similar to published inter-
national experience.
Plerixafor use decreased signiﬁcantly when it was no
longer freely available. This may be a reﬂection of limited
resources, a lack of belief in the preemptive use of plerixafor
or knowledge of the most cost-effective way to use it. The
pharmacoeconomics of mobilization likely vary from centre
to centre and are affected by multiple factors such as the
patient population, infrastructure, available resources, and
who is paying for plerixafor.154
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Background: Collection of a minimum number of hemato-
poietic progenitor cells (HPC), usually deﬁned as 2 x 106
CD34+ cells/kg, is required to ensure timely neutrophil and
platelet recovery.1-4 The majority of centres use peripheral
blood-mobilized HPCs as the source of progenitor cells for
autologous transplantation,5 but the method used to predict
the ﬁnal apheresis product CD34+ cell content, and thus the
whole blood volume to process during apheresis collection,
has not been standardized. In the mid-1990s, Mitterer et al.
demonstrated on a 28-patient cohort that the correlation
between the pre-apheresis peripheral blood CD34+ cell
count and the number of CD34+ cells/kg collected could be
used to determine the blood volume to process during
apheresis to harvest the desired number of CD34+ cells/kg
(target-value tailored, TVT, collection). Using this concept
and local data, the Ottawa Canadian Blood Services Stem Cell
Laboratory created a similar regression model to help
determine the blood volume to process during apheresis
collection.
Methods: We conducted a retrospective study of all pe-
ripheral blood HPC apheresis collections performed at the
Ottawa Hospital from January 1, 2003 to December 31, 2011.
Our objective was to validate the TVT approach, as modiﬁed
by our institution.
Results: From 2003 to 2011, there were 815 peripheral blood
HPC collections by apheresis. The majority, 696 (85.4%), were
autologous collections and 119 (14.6%) were allogeneic do-
nors. The most common diagnoses were multiple myeloma
and aggressive non-Hodgkin lymphoma (NHL). The median
age of the cohort was 51.1 (range 14.3 e 70.4) years. The
median number of prior chemotherapy regimens was 1
(range 0 e 5). The majority of collections, 635 (93.7%), were
ﬁrst attempts.
The median pre-collection peripheral blood CD34+ cell
count was 2.23 (interquartile range, IQR 1.07 e 5)/mL. The
